Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Описание к видео Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

PROSTAID Calgary's 2022 Pathfinder Award went to Dr. Geoffrey Gotto, clinical oncologist at the Southern Alberta Institute of Urology. Dr. Gotto was gracious enough to give us a presentation afterward on new research and innovations in metastatic castration-sensitive prostate cancer (MCSPC) that is leading to longer survival and greater quality of life in prostate cancer patients who do combinations of treatments to combat the cancer.

Комментарии

Информация по комментариям в разработке